Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAIME G DEVILLE

Allopathic & Osteopathic Physicians Pediatrics Pediatric Infectious Diseases

NPI
1750301503
CMS profile
306772
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$119.70

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $119.70 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
ViiV Healthcare Company $119.70 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAIME G DEVILLE

NPI 1750301503 · CMS profile ID 306772

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Infectious Diseases

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750301503?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAIME G DEVILLE, NPI 1750301503, CMS profile ID 306772. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750301503?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JAIME G DEVILLE, NPI 1750301503, CMS profile ID 306772. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750301503?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JAIME G DEVILLE, NPI 1750301503, CMS profile ID 306772, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1750301503?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $119.70 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ViiV Healthcare Company $119.7010/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671586299 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $119.70 1
PY2023 $12,707.12 13
PY2024 $184.08 4
PY2025 $2,569.53 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,582.34 15
PY2025 Principal investigator $260,502.25 43
PY2024 Principal investigator $147,535.10 28
PY2023 Recipient $2,359.23 6
PY2023 Principal investigator $286,959.88 51
PY2022 Principal investigator $147,785.97 35
PY2021 Recipient $31,165.00 1
PY2021 Principal investigator $320,361.44 168
PY2020 Principal investigator $484,980.10 158
PY2019 Principal investigator $153,612.59 56

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

169 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ViiV Healthcare Company $3,780.00 12/21/2021 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 860858161
Principal investigator 1 Gilead Sciences, Inc. $1,985.00 12/15/2021 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants from Birth to < 18 Years of Age with COVID-19 No dispute reported 06/30/2026 803514593
Recipient Eli Lilly and Company $31,165.00 11/29/2021 Covered Recipient Physician A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 819444443
Principal investigator 1 PFIZER INC. $9,393.12 11/23/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832848477
Principal investigator 1 ViiV Healthcare Company $2,306.30 11/16/2021 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA LA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 860858159
Principal investigator 1 PFIZER INC. $1,242.99 11/05/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832891103
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054077
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054079
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054081
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054083
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054085
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054087
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054089
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054091
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054093
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054095
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054097
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054099
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054101
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054103
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054105
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054107
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054109
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054111
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054113
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054115
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054117
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054119
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054121
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054123
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054125
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054127
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054129
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054131
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054133
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054135
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054137
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054139
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054141
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054143
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054145
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054147
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054149
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054151
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054153
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054155
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054157
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054159
Principal investigator 1 PFIZER INC. $4,725.00 10/21/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832844369
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $630.00 10/21/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 809477347
Principal investigator 1 PFIZER INC. $820.26 10/08/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832831543
Principal investigator 1 Astellas US Technologies $324.85 10/06/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054325
Principal investigator 1 Astellas US Technologies $324.85 10/06/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054327
Principal investigator 1 Astellas US Technologies $324.85 10/06/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054329
Principal investigator 1 Astellas US Technologies $324.85 10/06/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054331
Principal investigator 1 Astellas US Technologies $324.85 10/06/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054333
Principal investigator 1 Astellas US Technologies $324.85 10/06/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054335
Principal investigator 1 Astellas US Technologies $324.85 10/06/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054337
Principal investigator 1 Astellas US Technologies $324.85 10/06/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054339
Principal investigator 1 Astellas US Technologies $324.85 10/06/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054341
Principal investigator 1 Astellas US Technologies $324.85 10/06/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054343
Principal investigator 1 Astellas US Technologies $324.85 10/06/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054345
Principal investigator 1 Astellas US Technologies $324.85 10/06/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054347
Principal investigator 1 Gilead Sciences, Inc. $3,560.00 10/06/2021 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants from Birth to < 18 Years of Age with COVID-19 No dispute reported 06/30/2026 803514591
Principal investigator 1 Gilead Sciences, Inc. $3,150.00 09/29/2021 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 803514589
Principal investigator 1 ViiV Healthcare Company $562.83 09/16/2021 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA LA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 860858163
Principal investigator 1 PFIZER INC. $2,283.12 09/04/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832752073
Principal investigator 1 ViiV Healthcare Company $1,742.98 08/31/2021 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA LA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 860858157
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $6,300.00 08/24/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 809477343
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $2,142.00 08/24/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 809477345
Principal investigator 1 PFIZER INC. $422.73 08/21/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832728727
Principal investigator 1 PFIZER INC. $2,283.12 08/06/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832807679
Principal investigator 1 Merck Sharp & Dohme Corporation $433.80 07/23/2021 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA NICHD CRS
IMPAACT P1115, Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission A Phase I,II Proof of Concept Study No dispute reported 06/30/2026 848767067
Principal investigator 1 Gilead Sciences, Inc. $3,150.00 06/23/2021 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 803514587
Principal investigator 1 Gilead Sciences, Inc. $7,971.00 06/16/2021 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 803514585
Principal investigator 1 Astellas Pharma Global Development $30,154.00 05/13/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 801079063
Principal investigator 1 Gilead Sciences, Inc. $1,985.00 04/28/2021 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants from Birth to < 18 Years of Age with COVID-19 No dispute reported 06/30/2026 803514583
Principal investigator 1 Astellas US Technologies $324.85 04/20/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054323
Principal investigator 1 Astellas US Technologies $324.85 04/19/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054321
Principal investigator 1 Astellas US Technologies $324.85 04/18/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054319
Principal investigator 1 Astellas US Technologies $324.85 04/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054317
Principal investigator 1 Astellas US Technologies $324.85 04/16/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054315
Principal investigator 1 Astellas US Technologies $324.85 04/15/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054313
Principal investigator 1 Astellas US Technologies $324.85 04/14/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054311
Principal investigator 1 Astellas US Technologies $324.85 04/13/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054309
Principal investigator 1 Astellas US Technologies $324.85 04/12/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054307
Principal investigator 1 Astellas US Technologies $324.85 04/11/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054305
Principal investigator 1 Astellas US Technologies $324.85 04/10/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054303
Principal investigator 1 PFIZER INC. $17,344.00 04/10/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832734301
Principal investigator 1 Astellas US Technologies $324.85 04/09/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054301
Principal investigator 1 Astellas US Technologies $324.85 04/08/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054299
Principal investigator 1 Astellas US Technologies $324.85 04/07/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054297
Principal investigator 1 Astellas US Technologies $324.85 04/06/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054295
Principal investigator 1 Astellas US Technologies $324.85 04/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054293
Principal investigator 1 Astellas US Technologies $324.85 04/04/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054291
Principal investigator 1 Astellas US Technologies $324.85 04/03/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054289
Principal investigator 1 Astellas US Technologies $324.85 04/02/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054287
Principal investigator 1 Astellas US Technologies $324.85 04/01/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054285
Principal investigator 1 Astellas US Technologies $324.85 03/31/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054283
Principal investigator 1 Astellas US Technologies $324.85 03/30/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054281
Principal investigator 1 Astellas US Technologies $324.85 03/29/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054279
Principal investigator 1 Astellas US Technologies $324.85 03/28/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054277
Principal investigator 1 Astellas US Technologies $324.85 03/27/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054275
Principal investigator 1 Astellas US Technologies $324.85 03/26/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054273
Principal investigator 1 Astellas US Technologies $324.85 03/25/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054271
Principal investigator 1 Astellas US Technologies $324.85 03/24/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054269
Principal investigator 1 Astellas US Technologies $324.85 03/23/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054267
Principal investigator 1 Astellas US Technologies $324.85 03/22/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054265
Principal investigator 1 Astellas US Technologies $324.85 03/21/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054263
Principal investigator 1 Astellas US Technologies $324.85 03/20/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054261
Principal investigator 1 Astellas US Technologies $324.85 03/19/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054259
Principal investigator 1 Astellas US Technologies $324.85 03/18/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054257
Principal investigator 1 Astellas US Technologies $324.85 03/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054255
Principal investigator 1 Gilead Sciences, Inc. $5,976.00 03/17/2021 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants from Birth to < 18 Years of Age with COVID-19 No dispute reported 06/30/2026 803514581
Principal investigator 1 Astellas US Technologies $324.85 03/16/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054253
Principal investigator 1 Astellas US Technologies $324.85 03/15/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054251
Principal investigator 1 Astellas US Technologies $324.85 03/14/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054249
Principal investigator 1 Astellas US Technologies $324.85 03/13/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054247
Principal investigator 1 Astellas US Technologies $324.85 03/12/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054245
Principal investigator 1 Astellas US Technologies $324.85 03/11/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054243
Principal investigator 1 Astellas US Technologies $324.85 03/10/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054241
Principal investigator 1 Astellas US Technologies $324.85 03/09/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054239
Principal investigator 1 Astellas US Technologies $324.85 03/08/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054237
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054199
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054201
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054203
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054205
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054207
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054209
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054211
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054213
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054215
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054217
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054219
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054221
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054223
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054225
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054227
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054229
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054231
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054233
Principal investigator 1 Astellas US Technologies $324.85 03/05/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054235
Principal investigator 1 ViiV Healthcare Company $786.44 02/26/2021 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 803291687
Principal investigator 1 Astellas Pharma Global Development $44,081.00 02/25/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 801079043
Principal investigator 1 Eli Lilly and Company $3,180.89 02/22/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 819447851
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054161
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054163
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054165
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054167
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054169
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054171
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054173
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054175
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054177
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054179
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054181
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054183
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054185
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054187
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054189
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054191
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054193
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054195
Principal investigator 1 Astellas US Technologies $324.85 02/17/2021 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054197
Principal investigator 1 Gilead Sciences, Inc. $1,985.00 02/17/2021 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants from Birth to < 18 Years of Age with COVID-19 No dispute reported 06/30/2026 803514577
Principal investigator 1 Gilead Sciences, Inc. $71,531.00 02/17/2021 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants from Birth to < 18 Years of Age with COVID-19 No dispute reported 06/30/2026 803514579
Principal investigator 1 PFIZER INC. $15,750.00 02/05/2021 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832832089
Principal investigator 1 Gilead Sciences, Inc. $23,240.00 01/20/2021 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants from Birth to < 18 Years of Age with COVID-19 No dispute reported 06/30/2026 803514575
Principal investigator 1 ViiV Healthcare Company $1,284.26 01/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 803291685